Personal Care Wipes - Hangzhou Biogen Hygiene Co., Ltd. - page 1.
UPDATED: Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization | Fierce Biotech
Biogen's Qalsody Is a First for ALS Treatments - Bloomberg
How Biogen Became a Coronavirus 'Superspreader' - The New York Times
Biogen is ready to roll on lecanemab production, CFO says
Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer's Drug. | Barron's
Biogen shakes up R&D role, splitting it into two
Biogen gears up Swiss manufacturing facility for potential aducanumab rollout | Fierce Pharma
Drug companies are making an accounting change after the SEC cracked down on Biogen - MarketWatch
Dr BABOR Biogen Cellular - The Goddess Beauty and ...
CSRWire - Redefining What A Scientist Looks Like: Biogen Leaders Discuss the Importance of Women in STEM
Biogen Announces Positive Phase 1 Results, Plan to License and Develop Ionis Pharmaceuticals' Investigational Therapy BIIB067 for Familial ALS - Muscular Dystrophy Association
Biogen teams up with Ginkgo Bioworks in gene therapy manufacturing pact - MedCity News
Biogen and Alcyone Therapeutics partner up for novel device for neurological ASO therapies
Judge axes Biogen class action, rips shareholder lawyers for 'constant misrepresentation' | Reuters
More Layoffs Hit Biogen as Drugmaker Cuts Multiple Sclerosis Team – NBC Boston
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity
Biogen's new Alzheimer's drug slows cognitive decline: study - Boston Business Journal
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research | The Scientist Magazine®
Biogen (BIIB) Loses Bid to Revive Patent on Tecfidera MS Drug - Bloomberg
Biogen, at a Crossroads, Surges on Promising Alzheimer's Drug Assessment - WSJ
Biogen Wins US Approval for Drug to Treat Rare Form of ALS - BNN Bloomberg
Biogen's ALS Drug Tofersen Gets Partial Backing From FDA Panel - Bloomberg
Biogen and Novartis release Q1 earnings reports: Mixed results and hope for 2023
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
